'Zoledronic acid' diaporamas de présentation

Survivorship, Patient Engagement & Side Effect Management

Survivorship, Patient Engagement & Side Effect Management. LLS Multiple Myeloma Conference Pewaukee, WI October 5, 2013 (updated post conference) Mike Thompson, MD, PhD @ mtmdphd Medical Director Early Cancer Research Program, Patient-Centered Research Aurora Research Institute.

1.07k views • 87 slides

Long-term Management of Osteoporosis March 25, 2013

Long-term Management of Osteoporosis March 25, 2013. Ronald C. Hamdy , MD, FRCP, FACP Professor of Medicine Cecile Cox Quillen Chair of Geriatric Medicine Director, Osteoporosis Center East Tennessee State University. R. C. Hamdy - Disclosures.

940 views • 75 slides

Pharmacologic Treatments of Pain

Pharmacologic Treatments of Pain . PMRC Nursing Module Kim Chapman RN, MSc(N), CON(C) Clinical Nurse Specialist, Oncology October 2, 2009. Learning Objectives. Understand the spectrum of pain pharmacology Choose pharmacologic treatment options in chronic and cancer pain

1.31k views • 72 slides

Established Benefits of Bisphosphonates; Focus on Breast and Prostate Cancers

743 views • 53 slides

739 views • 50 slides

651 views • 50 slides

Hutchinson-Gilford progeria syndrome (HGPS)

Hutchinson-Gilford progeria syndrome (HGPS). PRESENTATION BY DELTA CELL. OUTLINE. BACKGROUND: Etymology and History EPIDEMIOLOGY AETIOPATHOGENESIS CLINICAL FEATURES DIFFERENTIAL DIAGNOSES

1.49k views • 48 slides

Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield

Breast Cancer and Bone Health. Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield. Breast Cancer and Bone Health. Normal Bone Health Impact of Cancer Therapies on Bone Health Therapeutic Strategies Management Guidelines. Breast Cancer and Bone Health.

624 views • 47 slides

Bondronat achieves better outcomes in metastatic bone disease

Bondronat achieves better outcomes in metastatic bone disease. Ingo Diel CGG-Klinik GmbH Mannheim, Germany. Keypad question 1. What bisphosphonate do you mainly use for treating metastatic bone disease? Clodronate Pamidronate Zoledronic acid Bondronat. Keypad question 2.

641 views • 43 slides

Palliative Care Delivery in South Trinidad

Dr Dylan Narinesingh and Team Presenters : Dr P.Sylvester and Dr N.Bhim. Palliative Care Delivery in South Trinidad. Inpatient setting. Assess and treat symptomatically Family meeting concerning options for home care vs hospice care Home care not feasible ? referral to Hospice

592 views • 40 slides

782 views • 37 slides

Hypercalcemia

Hypercalcemia. Carol S. Viele RN MS Clinical Nurse Specialist Hematology-Onc-BMT UCSF. Objectives. At the completion of this presentation the participant will be able to: Describe 2 side effects of hypercalcemia Define 2 agents utilized to treat hypercalcemia

911 views • 31 slides

Julie R. Gralow, M.D. Director, Breast Medical Oncology, Seattle ??? Care Alliance

??????? ???????? ? ????? ? ???????? ????. Julie R. Gralow, M.D. Director, Breast Medical Oncology, Seattle ??? Care Alliance Professor, Medical Oncology, University of Washington School of Medicine Member, Clinical Division, Fred Hutchinson ??? Research Center.

436 views • 30 slides

Achy Breaky Bones

389 views • 29 slides

Calcium Disorders

329 views • 27 slides

Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04)

Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04). Coleman RE et al. Proc SABCS 2010;Abstract S4-5. Endpoints. Primary: Disease-free survival (DFS) Secondary: Invasive DFS (IDFS) Overall survival (OS) Bone metastasis-free survival (BMFS)

343 views • 12 slides

Gnant M et al. Proc SABCS 2010;Abstract P5-11-02.

The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid with Adjuvant Endocrine Therapy Persist Long after Completion of Therapy. Gnant M et al. Proc SABCS 2010;Abstract P5-11-02. Endpoints.

383 views • 11 slides

Oncologic Drugs Advisory Committee Bethesda, Maryland January 31, 2002

C. Oncologic Drugs Advisory Committee Bethesda, Maryland January 31, 2002. C. Introduction. Burkhard Daldrup, PhD Global Head, Drug Regulatory Affairs Oncology Business Unit Novartis Pharmaceuticals Corporation. ZOMETA belongs to a new class of highly potent bisphosphonates

240 views • 9 slides

Authors: Fizazi K et al, ASCO 2010 Abstract: LBA4507 Reviewed by: Dr. Lori Wood

A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer (CRPC). Authors: Fizazi K et al, ASCO 2010 Abstract: LBA4507 Reviewed by: Dr. Lori Wood Date posted: Jun 18 2010.

180 views • 7 slides

Goserelin 3.6 mg q28d Tamoxifen 20 mg/d

Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12.

222 views • 6 slides